Apogee Therapeutics (APGE) Cash & Equivalents (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash & Equivalents data on file, last reported at $451.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 322.57% year-over-year to $451.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $451.8 million (up 322.57% YoY) and the FY2025 annual result came in at $131.5 million, down 7.22% from the prior year.
• Cash & Equivalents advanced to $451.8 million in Q1 2026 per APGE's latest filing, from $131.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $485.5 million in Q1 2024 and bottomed at $5.0 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $128.3 million (2023), against an average of $183.2 million.
• The widest annual swing landed in 2023, when Cash & Equivalents soared 2415.08%; it then plunged 77.98% in 2025.
• Tracing APGE's Cash & Equivalents over 5 years: stood at $151.9 million in 2022, then decreased by 22.1% to $118.3 million in 2023, then increased by 19.84% to $141.8 million in 2024, then declined by 7.22% to $131.5 million in 2025, then jumped by 243.44% to $451.8 million in 2026.
• Per Business Quant, the three latest APGE Cash & Equivalents figures stand at $451.8 million (Q1 2026), $131.5 million (Q4 2025), and $107.9 million (Q3 2025).

Peer Comparison